Disrupted S1P signalling and altered expression level has been implicated in a wide range of diseases including autoimmune diseases such as rheumatoid arthritis [4, 11] and neurodegenerative diseases such as multiple sclerosis (MS) [12], Alzheimer’s disease (AD) [13], Parkinson’s disease, and Huntington’s disease [1, 4, 14]. Here, MBTPS1 is linked to myeloid sarcoma.